Blueprint Medicines Corp Stock Today

BPMC Stock  USD 88.81  1.84  2.12%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 39

 
High
 
Low
Below Average
Blueprint Medicines is trading at 88.81 as of the 12th of October 2024, a 2.12% increase since the beginning of the trading day. The stock's open price was 86.97. Blueprint Medicines has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Blueprint Medicines Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2022 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of April 2015
Category
Healthcare
Classification
Health Care
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. The company has 63.35 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 5.26 trading days to cover. More on Blueprint Medicines Corp

Moving together with Blueprint Stock

  0.91ME 23Andme HoldingPairCorr

Moving against Blueprint Stock

  0.76VCYT VeracytePairCorr
  0.68DMAC DiaMedica TherapeuticsPairCorr
  0.61A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.53DNLI Denali TherapeuticsPairCorr
  0.53VERA Vera TherapeuticsPairCorr
  0.53DRTS Alpha Tau MedicalPairCorr

Blueprint Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentKathryn MBA
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.120.2377
Way Down
Slightly volatile
Total Current Liabilities225.7 M214.9 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total738.9 M703.7 M
Sufficiently Up
Slightly volatile
Total Assets784.9 MB
Way Down
Slightly volatile
Total Current Assets548 M808.4 M
Way Down
Slightly volatile
Debt Levels
Blueprint Medicines can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Blueprint Medicines' financial leverage. It provides some insight into what part of Blueprint Medicines' total assets is financed by creditors.
Liquidity
Blueprint Medicines Corp currently holds 774.12 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Blueprint Medicines Corp has a current ratio of 5.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Blueprint Medicines' use of debt, we should always consider it together with its cash and equity.

Stock Based Compensation

47.05 Million
Blueprint Medicines Corp (BPMC) is traded on NASDAQ Exchange in USA. It is located in 45 Sidney Street, Cambridge, MA, United States, 02139 and employs 638 people. Blueprint Medicines is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.63 B. Blueprint Medicines Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.35 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 5.26 trading days to cover. Blueprint Medicines Corp currently holds about 853.11 M in cash with (436.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28.
Check Blueprint Medicines Probability Of Bankruptcy
Ownership Allocation
The majority of Blueprint Medicines Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Blueprint Medicines Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Blueprint Medicines. Please pay attention to any change in the institutional holdings of Blueprint Medicines Corp as this could imply that something significant has changed or is about to change at the company.
Check Blueprint Ownership Details

Blueprint Stock Institutional Holders

InstituionRecorded OnShares
Lord, Abbett & Co Llc2024-06-30
1.2 M
Alliancebernstein L.p.2024-06-30
1.1 M
Pictet Asset Manangement Sa2024-06-30
1.1 M
Holocene Advisors, Lp2024-06-30
943.5 K
Amvescap Plc.2024-06-30
932.4 K
Alkeon Capital Management, Llc2024-06-30
893.9 K
Woodline Partners Lp2024-06-30
880.1 K
Polar Capital Holdings Plc2024-06-30
875 K
American Century Companies Inc2024-06-30
802.7 K
Blackrock Inc2024-06-30
6.6 M
Vanguard Group Inc2024-06-30
6.5 M
View Blueprint Medicines Diagnostics

Blueprint Medicines Historical Income Statement

At present, Blueprint Medicines' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 236.2 M, whereas Depreciation And Amortization is forecasted to decline to about 7.7 M. View More Fundamentals

Blueprint Stock Against Markets

Blueprint Medicines Corporate Management

Dr MBAChief OfficerProfile
Ariel HurleyPrincipal Accounting OfficerProfile
Tracey EsqChief VPProfile
Christina RossiChief Commercial OfficerProfile
Kathryn HavilandChief Business OfficerProfile
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.41)
Revenue Per Share
5.899
Quarterly Revenue Growth
1.4
Return On Assets
(0.19)
Return On Equity
(0.65)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.